Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nico Pfeifer

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Cell|July 17, 2020
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsChristoph Kreer, Matthias Zehner, Timm Weber, et al.
Cell|September 18, 2020
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsChristoph Kreer, Matthias Zehner, Timm Weber, et al.
Neuro-Oncology Practice|May 13, 2024
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE)Lorenz Dörner, Lucia Grosse, Felix Stange, et al.
Elife|October 31, 2013
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral controlIstván Bartha, Jonathan M Carlson, Chanson J Brumme, et al.
Experimental & Molecular Medicine|March 3, 2018
Whither systems medicine?Rolf Apweiler, Tim Beissbarth, Michael R Berthold, et al.
Nature Medicine|May 17, 2016
Impact of pre-adapted HIV transmissionJonathan M Carlson, Victor Y Du, Nico Pfeifer, et al.
Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.
Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.
Nature Medicine|January 17, 2017
Antibody 10-1074 suppresses viremia in HIV-1-infected individualsMarina Caskey, Till Schoofs, Henning Gruell, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Cell|July 17, 2020
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsChristoph Kreer, Matthias Zehner, Timm Weber, et al.
Cell|September 18, 2020
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 PatientsChristoph Kreer, Matthias Zehner, Timm Weber, et al.
Neuro-Oncology Practice|May 13, 2024
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE)Lorenz Dörner, Lucia Grosse, Felix Stange, et al.
Elife|October 31, 2013
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral controlIstván Bartha, Jonathan M Carlson, Chanson J Brumme, et al.
Experimental & Molecular Medicine|March 3, 2018
Whither systems medicine?Rolf Apweiler, Tim Beissbarth, Michael R Berthold, et al.
Nature Medicine|May 17, 2016
Impact of pre-adapted HIV transmissionJonathan M Carlson, Victor Y Du, Nico Pfeifer, et al.
Nature Medicine|September 28, 2018
Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individualsYotam Bar-On, Henning Gruell, Till Schoofs, et al.
Nature|June 25, 2016
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruptionJohannes F Scheid, Joshua A Horwitz, Yotam Bar-On, et al.
Nature Medicine|January 17, 2017
Antibody 10-1074 suppresses viremia in HIV-1-infected individualsMarina Caskey, Till Schoofs, Henning Gruell, et al.
Nature|September 28, 2018
Combination therapy with anti-HIV-1 antibodies maintains viral suppressionPilar Mendoza, Henning Gruell, Lilian Nogueira, et al.
Pageof 10